Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Gusztav Milotay

DPhil Student

Prior to starting a DPhil, I worked in a TCR therapeutics company called Etcembly where I contributed to the development of a microfluidics platform for peripheral immune repertoire sequencing. I am now looking to expand on single cell approaches to try and deorphanise TCRs in melanoma patients who respond to checkpoint immunotherapy and potentially leverage this to probe the relationship between response and toxicity.